| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| ln Vivo |
Antidepressant-like effect in mice:
Male ICR mice were used, divided into control group (0.5% carboxymethyl cellulose sodium, CMC-Na), Bacopaside I treatment groups (10 mg/kg, 20 mg/kg, 40 mg/kg), and positive control group (imipramine 15 mg/kg). Behavioral tests and biochemical analyses were conducted after 7 days of administration: 1. Behavioral test results: - Forced Swim Test (FST): Bacopaside I dose-dependently reduced immobility time. The 40 mg/kg group had the most significant effect, with immobility time reduced by 42.3 ± 3.5% compared to the control group [2] - Tail Suspension Test (TST): The 20 mg/kg and 40 mg/kg groups showed reduced immobility time; the 40 mg/kg group had a 38.6 ± 2.8% reduction vs control [2] 2. Interaction with noradrenergic system: - Co-administration of Bacopaside I (20 mg/kg) with yohimbine (α2-adrenergic antagonist, 1 mg/kg) enhanced the antidepressant effect, further reducing FST immobility time by 25.1 ± 2.1% vs Bacopaside I alone [2] - Co-administration with propranolol (β-adrenergic antagonist, 10 mg/kg) reversed the antidepressant effect of Bacopaside I (20 mg/kg), increasing FST immobility time by 31.4 ± 2.3% vs Bacopaside I alone [2] 3. Oxidative stress indicators: - Bacopaside I (40 mg/kg) reduced malondialdehyde (MDA) level in mouse brain tissue by 35.2 ± 3.1% and increased glutathione peroxidase (GSH-Px) activity by 41.5 ± 3.6% compared to the control group [2] |
|---|---|
| Animal Protocol |
Antidepressant experiment in mice:
1. Animal preparation: Male ICR mice (20-22 g) were housed in a controlled environment (23±1°C, 12-hour light/dark cycle) with free access to food and water. They were acclimated for 7 days before the experiment [2] 2. Drug preparation and administration: - Bacopaside I was dissolved in 0.5% CMC-Na to prepare solutions of 1 mg/mL, 2 mg/mL, and 4 mg/mL [2] - Mice in treatment groups received intraperitoneal injection of Bacopaside I at 10 mg/kg, 20 mg/kg, or 40 mg/kg (0.1 mL/10 g body weight) once daily for 7 consecutive days [2] - The control group received 0.5% CMC-Na (equal volume), and the positive control group received imipramine (15 mg/kg, intraperitoneal injection) [2] 3. Behavioral tests: - FST: Mice were placed in a cylindrical tank (25 cm diameter, 30 cm height, water depth 15 cm, 25±1°C) for 6 minutes; immobility time was recorded in the last 4 minutes [2] - TST: Mice were suspended by the tail (1 cm from the tip) for 6 minutes; immobility time was recorded in the last 4 minutes [2] 4. Biochemical detection: After behavioral tests, mice were sacrificed, and brain tissues were collected. MDA level and GSH-Px activity were detected using corresponding assay kits [2] |
| References | |
| Additional Infomation |
It has been reported that purslane contains purslane glycoside I, and there are related data reports.
1. Background of purslane glycoside I: Purslane glycoside I is a pseudojujube glycoside, which was isolated from the aerial parts of the medicinal plant purslane (Scrophulariaceae)[1] 2. Antidepressant mechanism: The antidepressant-like effect of purslane glycoside I may involve two pathways: (1) regulation of the norepinephrine system (confirmed by interaction with α2/β-adrenergic antagonists); (2) reduction of oxidative stress in brain tissue (by reducing MDA levels and increasing GSH-Px activity)[2] 3. Significance of the study: This study provides experimental evidence for the antidepressant potential of purslane glycoside I, supporting its further development as a candidate drug for the treatment of depression[2] |
| Molecular Formula |
C46H74O20S
|
|---|---|
| Molecular Weight |
979.1328
|
| Exact Mass |
978.449
|
| CAS # |
382148-47-2
|
| PubChem CID |
21599442
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.48±0.1 g/cm3 (20 ºC 760 Torr)
|
| LogP |
1.371
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
20
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
67
|
| Complexity |
1970
|
| Defined Atom Stereocenter Count |
24
|
| SMILES |
CC(=C[C@@H]1CO[C@]23C[C@]4(CO2)[C@@H]([C@H]3[C@@]1(C)O)CC[C@H]5[C@]4(CC[C@@H]6[C@@]5(CC[C@@H](C6(C)C)O[C@H]7[C@@H]([C@H]([C@H](CO7)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)COS(=O)(=O)O)O)O)O)O[C@H]9[C@@H]([C@H]([C@@H](O9)CO)O)O)C)C)C
|
| InChi Key |
SKFWOYHZBNAJGA-YAOMZRCFSA-N
|
| InChi Code |
InChI=1S/C46H74O20S/c1-21(2)14-22-16-59-46-19-45(20-60-46)23(37(46)44(22,7)54)8-9-28-42(5)12-11-29(41(3,4)27(42)10-13-43(28,45)6)64-40-36(66-38-33(52)30(49)25(15-47)62-38)35(24(48)17-58-40)65-39-34(53)32(51)31(50)26(63-39)18-61-67(55,56)57/h14,22-40,47-54H,8-13,15-20H2,1-7H3,(H,55,56,57)/t22-,23-,24+,25+,26-,27+,28-,29+,30+,31-,32+,33-,34-,35+,36-,37+,38+,39+,40+,42+,43-,44+,45+,46-/m1/s1
|
| Chemical Name |
[(2R,3S,4S,5R,6S)-6-[(2S,3R,4S,5S)-3-[(2S,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-5-hydroxy-2-[[(1S,2R,5R,7S,10R,11R,14R,15S,16S,17R,20R)-16-hydroxy-2,6,6,10,16-pentamethyl-17-(2-methylprop-1-enyl)-19,21-dioxahexacyclo[18.2.1.01,14.02,11.05,10.015,20]tricosan-7-yl]oxy]oxan-4-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl hydrogen sulfate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~102.13 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.55 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.55 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.55 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0213 mL | 5.1066 mL | 10.2131 mL | |
| 5 mM | 0.2043 mL | 1.0213 mL | 2.0426 mL | |
| 10 mM | 0.1021 mL | 0.5107 mL | 1.0213 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
